PMI’s smoke-free product assessment approach
Our scientific assessment is built on a collaborative approach and expertise in the fields of chemistry, biology, informatics, and medicine. Our practices are inspired by the pharmaceutical industry and are aligned to the draft guidance issued by the U.S. Food and Drug Administration’s Center for Tobacco Products in 2012. This is a brief overview of our assessment program.
Platform Development
What is the scientific basis of the development of our smoke-free products?
Toxicological assessment
We assess our smoke-free products in vitro and in vivo to verify their potential to reduce individual health risk compared with continued smoking.
Clinical assessment
Our clinical studies provide information on how the body responds when smokers switch to our smoke-free products, and how this differs from continued smoking or quitting for the duration of these studies.
Perception and behavior assessment
We assess the impact of potential communication on adult consumers, and how this might influence their risk perception and usage of our smoke-free products.
Long-term assessment
Our program monitors events linked to the usage of our smoke-free products and also studies the effects of switching.
